Related Experiment Video
Updated: Jun 5, 2026

Unveiling Xenobiotic Transport and Effects in Isolated Mitochondria: Insights from Respirometric and Enzymatic Assays
Published on: March 7, 2025
Mitotane has a strong and a durable inducing effect on CYP3A4 activity
Nielka P van Erp1, Henk-Jan Guchelaar, Bart A Ploeger
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, Postal zone L0-P, 2300 RC Leiden, The Netherlands. p.h.van_erp@lumc.nl
Mitotane significantly induces CYP3A4 activity, leading to reduced exposure of drugs like midazolam and sunitinib. This effect is long-lasting and has clinical implications for patients on multiple medications.
Area of Science:
- Pharmacology
- Drug Metabolism
- Oncology
Background:
- The pharmacokinetic effects of mitotane on co-administered drugs are largely unknown.
- Adrenocortical carcinoma (ACC) patients often receive mitotane therapy.
- Understanding drug interactions is crucial for effective cancer treatment.
Purpose of the Study:
- To investigate the impact of mitotane on the pharmacokinetics of midazolam and sunitinib.
- To assess the effect of mitotane on CYP3A4 enzyme activity.
Main Methods:
- A sunitinib pharmacokinetic study serendipitously identified effects in mitotane-treated ACC patients.
- Midazolam was used as a phenotypic probe for CYP3A4 activity.
- Pharmacokinetic analyses of midazolam, 1-hydroxy-midazolam, and sunitinib were performed in mitotane-exposed and non-exposed patients.
Main Results:
- Mitotane-treated patients exhibited significantly induced CYP3A4 activity, evidenced by decreased midazolam and increased 1-hydroxy-midazolam exposure.
- This induction persisted even after mitotane therapy cessation.
- Sunitinib exposure was substantially reduced in patients co-administered mitotane.
Conclusions:
- Mitotane possesses a potent and enduring inducing effect on CYP3A4 activity.
- This strong induction can lead to clinically significant drug interactions.
- Caution is advised when co-administering mitotane with other drugs metabolized by CYP3A4.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Anthelminthic Agents
Drugs that Destabilize Microtubules
Pharmacokinetics: Drug–Drug Interactions
Drugs that Stabilize Microtubules